Safety, tolerability through 24 months was consistent with 12-month tofacitinib analysis. The approval for Idacio was based on a review of data that showed similar pharmacokinetics, efficacy, safety, ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Idacio as a biosimilar to Humira, a TNF inhibitor with indications for rheumatoid arthritis, ...
A biosimilar drug to the tumor necrosis factor inhibitor adalimumab, marketed as Idacio (adalimumab-aacf), has been approved by the Food and Drug Administration for use in the United States, according ...
Fresenius Kabi has obtained the Food and Drug Administration’s permission for its citrate-free adalimumab biosimilar Idacio for use in the treatment of chronic autoimmune diseases for all eligible ...
Blue Shield of California will purchase Idacio at $525 per dose, significantly cheaper than Humira's $2100 price, enhancing affordability for patients. Collaboration with Fresenius Kabi and Evio ...
TORONTO, Feb. 18, 2021 /CNW/ - Fresenius Kabi Canada, a health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results